Table 3.
Medication Prescription Rates Before and After PCI
| Medication | No. (%), (95% CI) of Patients | P‐Value | |
|---|---|---|---|
| Pre‐PCI (90 Days) | Post‐PCI (90 Days) | ||
| Optimal medical therapy | 33.9 (33.3 to 34.5) | 47.1 (46.5 to 47.7) | <0.001 |
| Suboptimal medical therapy | 50.2 (49.6 to 50.9) | 48.9 (48.3 to 49.6) | 0.001 |
| None | 15.9 (15.4 to 16.4) | 4.0 (3.7 to 4.2) | <0.001 |
| Individual medications | |||
| Long‐acting nitrate | 23.5 (23.0 to 24.1) | 14.5 (14.0 to 14.9) | <0.001 |
| β‐Blocker | 56.9 (56.2 to 57.5) | 70.6 (70.1 to 71.2) | <0.001 |
| Calcium channel blocker | 38.8 (38.1 to 39.4) | 30.9 (30.3 to 31.5) | <0.001 |
| Statin | 64.3 (63.6 to 64.9) | 84.6 (84.1 to 85.0) | <0.001 |
| ACE‐I/ARB | 62.3 (61.7 to 63.0) | 74.5 (73.9 to 75.0) | <0.001 |
| Clopidogrel | 22.7 (22.1 to 23.2) | 87.1 (86.7 to 87.5) | <0.001 |
| Symptom‐oriented medical therapy | 61.2 (60.6 to 61.8) | 57.9 (57.3 to 58.5) | <0.001 |
Optimal medical therapy is defined as prescription for β‐blocker, statin, and either ACE inhibitor or ARB in the 90 days prior to PCI, and the same medications along with a thienopyridine in the 90 days following PCI. Suboptimal therapy is defined as prescription of at least 1 of the above individual medications. Symptom‐oriented medical therapy is defined as prescription of any 2 medications from the following in the 90 days pre‐PCI: β‐blocker, long‐acting nitrate, calcium channel blocker or either ACE inhibitor or ARB, and the same medications along with a thienopyridine and statin in the 90 days following PCI. ACE indicates angiotensin‐converting enzyme; ARB, angiotensin receptor blocker; PCI, percutaneous coronary intervention.